Previous close | 11.08 |
Open | 11.10 |
Bid | 10.43 x 1000 |
Ask | 12.39 x 800 |
Day's range | 10.94 - 11.42 |
52-week range | 4.70 - 16.85 |
Volume | |
Avg. volume | 683,680 |
Market cap | 1.013B |
Beta (5Y monthly) | 1.46 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.09 |
Earnings date | 06 Nov 2023 - 21 Nov 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 19.89 |
Shares of Avadel Pharmaceuticals (NASDAQ: AVDL) were up as much as 45.5% for the week as of late Friday afternoon, according to data provided by S&P Global Market Intelligence. On Monday, it reported that the Food and Drug Administration (FDA) had approved the company's first product, Lumryz, to treat excessive daytime sleepiness in adults with narcolepsy. The drug, a formulation of sodium oxybate, is the first FDA-approved, once-at-bedtime oxybate for narcolepsy.